Abstract
Myeloid‐derived suppressor cells (MDSCs) mediate tumor‐associated immune suppression in both cancer patients and tumor‐bearing animals. Reduction or elimination of MDSCs reduces the rate of tumor progression and improves cancer therapies that employ mechanisms of immunity. Here we show that baccatin III, which is the precursor for the semisynthesis of paclitaxel, exerts antitumor immunomodulatory activity in very low doses (0.05 ‐ 0.5 mg/kg), although it is regarded as an inactive derivative of paclitaxel. Oral administration of baccatin III significantly reduced the growth of tumors induced by engrafting mice with either 4T1 mammary carcinoma or CT26 colon cancer cells. Antitumor activity was immune‐mediated because baccatin III was not directly cytotoxic. Baccatin III decreased the accumulation of MDSCs in the spleens of the tumor‐bearing mice. Furthermore, MDSCs isolated from baccatin III‐treated mice, compared with those isolated from vehicle‐treated mice, had a significantly reduced suppressive effect on T cells treated with the anti‐CD3 and anti‐CD28 monoclonal antibodies. Moreover, these cells produced significantly reduced amounts of reactive oxygen species and nitric oxide. These results demonstrate that baccatin III reduced tumor progression by inhibiting the accumulation and suppressive function of MDSCs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.